Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xdemvy for Demodex Blepharitis in Scleral Lens Wearers
NCT07561450Phase 4Completed
- Sponsor
- BostonSight
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lotilaner in Demodex blepharitis (DB), sponsored by BostonSight. Primary endpoints: Contact Lens Dry Eye Questionnaire-8 at Day 42 and Visual Analog Scale - Symptom and Lens Performance Scores at Day 42. Started Apr 2026; status: completed.
02
Drugs
lotilaner
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on NCT07561450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561450.